Tag: psilocybin

  • The Role of Psychedelic Plant Medicines in Addiction Treatment

    Psychedelic plant medicines have been used for healing purposes by indigenous cultures for thousands of years, and there is mounting evidence that shows their ability to integrate with modern addiction therapy. 

    Psychedelic plant medicines have the potential to help many people who are in recovery from substance use disorder dig deep into the roots of their addiction and come out of the other side. Plant medicines like psilocybin, ayahuasca, and particularly ibogaine, have demonstrated unprecedented results for those who use them as a tool on their recovery journey.

    While the legal status of many of these substances is still murky (depending on where you consume them), the ongoing research, decriminalization efforts, and shift in public narrative is promising. Hope lies on the horizon for wider access to these medicines, but right now, what’s needed is raising awareness and informed decision-making around their consumption.

    Here is how psychedelic plant medicines can help those that struggle with addiction and what people should consider before choosing this path.

    Ancient healing practices reconcile with modern science

    Psychedelic plant medicines have been used for healing purposes by indigenous cultures for thousands of years, and there is mounting evidence that shows their ability to integrate with modern addiction therapy. 

    Research around the potential of ibogaine to treat opiate addiction is still in its infancy, but shows promising results. Ibogaine, which comes from the Iboga shrub, has been used historically in ceremonies in West Africa by practitioners of the Bwiti spiritual tradition since the late nineteenth century. The roots and bark of the tree are consumed ceremoniously in large doses to provoke a near-death experience, and in smaller doses during rituals and tribal dances. It is not considered a recreational substance by users, yet is classified as a Schedule 1 drug in the US.

    One 2017 study funded by the Multidisciplinary Association for Psychedelic Studies (MAPS) observed opiate addiction treatment delivered by two independent ibogaine clinics in Mexico. One month after the study, half of participants reported using no opiates in the month following the study. The researchers found that “ibogaine was associated with substantive effects on opioid withdrawal symptoms and drug use in subjects for whom other treatments had been unsuccessful.” 

    Another study on the long-term efficacy of ibogaine-assisted therapy in New Zealand found that a single ibogaine treatment reduced opioid symptoms and resulted in no opioid use or reduced use in dependent individuals over 12 months. 

    Healing that gets to the root

    Ayahuasca is a psychoactive Amazonian brew traditionally used in the indigenous communities of South America. Research on the brew is grounded in its potential to support healing by allowing for a deeper connection to oneself and due to the spiritual context in which it is taken. 

    One 2017 study published in the International Journal on Drug Policy used qualitative analysis through long-term field work and participant observation in ayahuasca communities, as well as conducting interviews with participants with problems of substance abuse.

    The study found that “ayahuasca’s efficacy in the treatment of addiction blends somatic, symbolic, and collective dimensions. The layering of these effects, and the direction given to them through ritual, circumscribes the experience and provides tools to render it meaningful.”

    Researchers from a 2013 Canadian study, sponsored by MAPS, concluded that ayahuasca-assisted therapy for stress and addiction was correlated with improved mindfulness, empowerment, hopefulness, and quality of life-outlook and quality of life-meaning. The same study found that ayahuasca, when administered in a ceremonial setting, may have contributed to reduction in cocaine use in dependent participants.

    There have also been studies that show the benefit of psilocybin mushrooms in allowing people to overcome addictive or damaging behavior. A 2014 study from the Johns Hopkins Center for Psychedelic and Consciousness Research found that 80% of previously addicted smokers abstained from smoking six months after they were administered psilocybin. Remarkably, 60% continued to abstain two and a half years after the study.

    “Institutions like MAPS and the Imperial College London are pioneering the way forward with this evidence-based approach to psychedelic medicine—a necessary effort if these compounds are to be integrated into the mainstream,” said Gaurav Dubey, clinical biologist and content editor at Microdose Psychedelic Insights.

    “Though, we have a lot of catching up to do,” said Dubey. “We need to do better in understanding the psychotherapeutic mechanisms of these incredibly unique compounds and the only way to uncover that is through science and research.

    “The clinical data that strongly supports the therapeutic use of these compounds in addiction treatment will be fundamental in making them accessible to recovering addicts around the globe,” he added.

    Journeys to an addiction-free life, supported by plant medicines

    Kat Courtney is the founder of AfterLife Coaching, a trained ayahuasquera, and has been working with the plant medicine ayahuasca for over a decade. Courtney first began her journey with ayahuasca in Peru in 2006, while suffering with alcoholism and bulimia.

    “Not only did ayahuasca help me face and deal with the traumas and programming that created these destructive behaviors, she helped me access an authentic space of self love and gave me tools to work with in lieu of the addictions,” said Courtney.

    “They fast-track the healing and awakening process and ground us into our bodies so we can move past stages of self-destruction. They help us to move the trauma that is stored in the body through crying, purging, and all kinds of different forms of release.”

    But Courtney stresses that the act of taking these medicines is only part of the deal: “We absolutely have to be committed to integrating these experiences and making the life changes that support sobriety,” explained Courtney. “Otherwise, plant medicine ceremonies can become distant memories.”

    Alternative approaches offer a chance for healing

    Aeden Smith-Ahearn is the founder of Experience Ibogaine Clinic, based in Mexico. Aeden first tried ibogaine in an effort to overcome his dependency on multiple substances, including heroin

    “Ibogaine got me comfortably off opiates,” said Smith-Ahearn. “I had almost no withdrawal symptoms, and I had a very profound experience which helped give me a motivational boost in the right direction.

    “The medicine put me in my place, and that’s exactly where I needed to be. I got a fresh start, on top of a head start into my recovery,” he explained.

    Prior to his ibogaine experience, Smith-Ahearn had tried several programs in an attempt to break free from his addictions, which he describes as “cold turkey, three meals a day, and a therapist once a week.”

    “These programs work for many people, but they didn’t do the job for me. The problem was that I did not want to change, and was therefore unwilling to work towards something I didn’t want,” he said.

    Smith-Ahearn credits ibogaine with huge potential for recovering opiate addicts specifically because of how it interacts with the brain’s receptors. “The hardest part about breaking out of opiate addiction is getting over withdrawals,” he said. “The medicine alleviates withdrawal symptoms [for some patients], which is a godsend for someone who is in over their head with opiate addiction.”

    Like Courtney, Smith-Ahearn stresses that ibogaine is not a cure-all. “It’s crucial that patients of the treatment put their effort into a quality aftercare plan.”

    Charles Johnston, director of client success at Clear Sky Recovery, has also historically struggled with opiate addiction and subsequently used ibogaine as a tool to help him overcome his dependency.

    “Ibogaine was the medicine that interrupted my addiction, and for the first time let me fully witness the root cause of my addiction: self-hatred. It provided me with a path, purpose, and mission to support others and see that addiction is a blessing of self-discovery,” explained Johnston.

    “Ibogaine allows the individual to feel how they would after months of detox with conventional methods and if supported properly, encourages a whole new paradigm of accountability and acceptance,” he continued.

    With these and other accounts of personal transformation, it’s clear that ayahuasca and ibogaine have potential to assist people struggling with addiction on a path to recovery. However, these treatments should not be treated lightly and come with a number of risks to the patient if not administered responsibly.

    What you need to consider before trying psychedelic therapy

    Psychedelics generally have very little risk of abuse, but when taken in the wrong setting, or without proper guidance or structured preparation and integration, they can result in negative consequences.

    There are some short term health risks which are important to consider. “Using ibogaine comes with risks to your physical health, such as seizures, gastrointestinal issues, heart complications, and ataxia,” says board-certified psychiatrist and addiction specialist Dr. Zlatin Ivanov. “There have also been unexplained fatalities in people who have ingested ibogaine, which may be linked to the treatment.”

    Charles Johnston of Clear Sky Recovery explained that “if someone has heart issues, liver problems, other major health complications, serious psychological issues, or are expecting a quick fix, ibogaine may not be the right path.”

    The same largely goes for users of other plant medicines, including ayahuasca. Users of SSRI antidepressant medication have run into an adverse reaction while drinking the medicine with the drugs still in their system.

    “People need to do careful research and not fall foul of misleading things that they see on the internet. A lot of people have expectations that the medicine may not offer, like profound psychedelic experiences guaranteed to change them or no withdrawal whatsoever,” said Aeden Smith-Ahearn of Experience Ibogaine.

    Those seeking treatment with psychedelic plant medicines should make sure they go to a reliable and reputable center. In recent years, the number of tourists flocking to Peru to drink ayahuasca has boomed, resulting in illegitimate retreats run by people lacking in the experience required to administer the medicine.

    In many countries, including the US, these substances are illegal to consume. Many people do however seek out treatment in countries where the medicines are not outlawed, such as Mexico, Costa Rica, Peru, and Colombia. In the US, ayahuasca is legal within specific religious groups, such as the Santo Daime.

    A path to accessibility

    Looking ahead to the future of psychedelic treatment, progress is being made on the legalization front, with Oakland and Santa Cruz, California, and Denver, Colorado, voting for decriminalization of psilocybin-containing mushrooms in 2019 and 2020. Oregon and Washington D.C. also have votes ahead on the decriminalization of psychedelic-containing plants and fungi.

    Meanwhile, Canada is seeing a number of legal ayahuasca centers open up, on the part of religious groups who have special permission from the government to use the medicine. However, ultimately, it will be a continuation of the scientific research that paves the way for increased access to psychedelic therapy.

    “We need more large scale, gold-standard clinical trials examining these compounds in the context of addiction treatment, such that their impact can no longer be ignored—even by the most stubborn of policymakers and world leaders,” said Dubey.

    “There needs to be a shift in global drug policy so these powerful medicines can be reclassified and reintegrated into our society in an effort to heal the masses.”

    In essence, psychedelics need to go mainstream and lose the stigma that they have held for decades so that the public appetite can develop and further drive policy changes. In addition to research, diverse voices and experiences, along with mainstream support, will be key in the psychedelic renaissance maintaining its momentum.

    The value of psychedelic plant medicines for addiction recovery is difficult to overstate, but is a path that should be explored carefully, mindfully, and while armed with the right information and support. And there’s hope that a future where accessibility isn’t an issue is on the horizon: The ongoing research and changing societal attitudes towards psychedelic plant medicines demonstrate promise. Education around these medicines and their proper use is vital for this renaissance to continue.

    By shining a light on the potential of psychedelic plant medicines to help and heal, we can contribute to forming more pathways to change and legitimate channels for people to benefit from their treatment.

    View the original article at thefix.com

  • Psilocybin Trial Patients Describe Their "Trips" To Anderson Cooper

    Psilocybin Trial Patients Describe Their "Trips" To Anderson Cooper

    One of the trial’s participants quit smoking after 46 years. 

    In a recent 60 Minutes segment, Anderson Cooper interviewed multiple subjects of research trials exploring the effects of psilocybin on people living with depression, anxiety or addiction.

    Trials are ramping up after decades of total bans on any scientific research into psychedelic drugs such as psilocybin (“magic mushrooms”) and LSD. Many participants who have been put through six-hour experiences with psilocybin found them to be life-changing.

    “They come to a profound shift of world view,” says researcher Roland Griffiths, “and essentially, a shift in sense of self.”

    Cooper interviewed two trial participants who had been struggling with addiction for many years, having had no success with other quitting techniques and products. After one intense session with the psychedelic drug, they haven’t touched the substances that were troubling them since.

    46-Year Smoker Quits After “Bad Trip”

    Carine McLaughlin, a smoker for 46 years, was able to quit after having a “bad trip,” an experience that produced primarily negative or distressing emotions.

    “The ceiling of this room were clouds, like, heavy rain clouds,” McLaughlin recalled of her session. “And gradually they were lowering. And I thought I was gonna suffocate from the clouds.”

    Jon Kostakopoulos, meanwhile, was up to 20 drinks a night before his session, which brought up old memories and deep feelings.

    “I felt, you know, a lot of shame and embarrassment throughout one of the sessions about my drinking and how bad I felt for my parents to put up with all this,” he said. He hasn’t had a drink since that day in 2016. He hasn’t even been tempted, he said.

    “Not at all, which is the craziest thing because that was my favorite thing to do,” he told Cooper.

    Researcher Griffiths and his colleague Matthew Johnson have been working on their research since 2000, when the Nixon-era ban on psychedelics in scientific trials was lifted. Before the ban, similar trials were conducted with LSD in the 1950s and ’60s. 

    How It Works

    Today, Griffiths and Johnson are careful to weed out patients with psychotic disorders and family histories of schizophrenia or bipolar disorder and all trial participants are put through “weeks of intensive counseling before and after” the experience. After finally being given the dose of psilocybin, they lie on a couch with a blindfold and headphones playing “a mix of choral and classical music” while a guide watches over them.

    Results have been very promising, with the majority of the 51 terminal cancer patients who have been through the trial enjoying “significant decreases in depressed mood and anxiety” from the treatment.

    “It seemed so implausible to me that a single experience caused by a molecule, right, ingested in your body could transform your outlook on something as profound as death,” said How To Change Your Mind author Michael Pollan. “That’s kind of amazing.”

    View the original article at thefix.com

  • Oakland Could Be Next City To Decriminalize Psilocybin, Other Entheogenic Plants

    Oakland Could Be Next City To Decriminalize Psilocybin, Other Entheogenic Plants

    Earlier this month, Denver became the first US city to decriminalize psilocybin.

    The city of Oakland, California may become the second city in the United States to decriminalize psilocybin mushrooms (i.e. magic mushrooms), following the recent example of Denver.

    Early May, voters in Denver, Colorado approved a ballot initiative to decriminalize psilocybin mushrooms by a narrow margin, with 50.64% voting in favor of Ordinance 301. The measure does not legalize magic mushrooms, but effectively prohibits the city from prosecuting or arresting adults for possession.

    Now, Oakland city officials are considering doing the same.

    Oakland’s resolution, provided by Decriminalize Nature Oakland, specifically refers to the decriminalization of “entheogenic plants,” which in addition to psilocybin include ayahuasca, cacti (mescaline) and iboga—i.e. “the full spectrum of plants, fungi, and natural materials… that can inspire personal and spiritual well-being, can benefit psychological and physical wellness, and can reestablish human’s inalienable and direct relationship to nature.”

    The federal government has long classified psilocybin mushrooms under Schedule I—the category of drugs that are defined as having no medical value and a high potential for abuse. Drug policy reform advocates disagree with the federal government’s decision to classify drugs like psilocybin and cannabis under Schedule I, where heroin also resides.

    NBC Bay Area reported that Oakland officials planned to discuss the issue on Tuesday (May 28) at a public hearing before the City Council’s public safety committee. The issue could go before the full council as early as June 4, according to the San Francisco Chronicle.

    Councilman Noel Gallo introduced the resolution after being approached by Decriminalize Nature Oakland. Gallo told the Chronicle that the city’s mental health problem may benefit from the decriminalized use of psilocybin mushrooms, which has been studied for its medical properties.

    “We need all the help we can get to deal with the mental health issues that we have. If I can bring it publicly and talk about the benefit and talk about (how it can) deal with the mental illnesses that we have in the city, why not?” said Gallo.

    Researcher Matthew Johnson of Johns Hopkins University says there is reason to be optimistic about psilocybin’s abilities to have a positive impact on mental health issues such as PTSD, depression, addiction and more. “The data are really impressive,” he told the Chronicle. “We should be cautiously but enthusiastically pursuing these threads.”

    The Oakland measure also has the support of Council President Rebecca Kaplan. “I believe we need to continue to support efforts to help end mass incarceration and I recognize that the war on drugs has been a racist, expensive, wasteful failure. I also believe there are strong public health reasons to support this change,” she told the Chronicle.

    View the original article at thefix.com

  • Denver Becomes First State To Decriminalize Magic Mushrooms

    Denver Becomes First State To Decriminalize Magic Mushrooms

    The enforcement of laws around psilocybin will now be the lowest priority for Denver police.

    Voters in Denver, Colorado, one of the first areas in the country to push for legalized cannabis, have voted to decriminalize the possession of psychedelic mushrooms in a move some people believe could set the stage for the next major drug policy change after the widespread legalization of marijuana.

    “Our victory today is a clear signal to the rest of the country that Americans are ready for a conversation around psilocybin,” Kevin Matthews, director of the “Decriminalize Denver” campaign, told NPR.

    Although initial reports said that city voters had rejected decriminalization, an unofficial tally released by the city found that the measure passed with fewer that 2,000 votes. In the end, 50.56% of voters wanted mushrooms decriminalized.

    The measure will not change the legality of psychedelic mushrooms, which will remain a Schedule I substance that is illegal under state law in Colorado. However, it will make the enforcement of laws around psilocybin the lowest priority for Denver police, as long as the person in possession of the psychedelic is 21 or older.

    People can even grow the mushrooms for personal use without becoming a target for law enforcement, according to the measure.

    Proponents of magic mushrooms claim that, like cannabis, the substance has medical benefits and is extremely low risk. Matthews has said that so-called magic mushrooms helped him overcome debilitating depression.

    “Because psilocybin has such tremendous medical potential, there’s no reason individuals should be criminalized for using something that grows naturally,” Matthews said, according to The New York Times.

    One 2016 study found that “Participants attributed to the high-dose [psilocybin] experience positive changes in attitudes about life, self, mood, relationships and spirituality, with over 80% endorsing moderately or higher increased well-being or life satisfaction.”

    However, the Drug Enforcement Administration in Colorado reported that it would still enforce a ban on mushrooms. Denver District Attorney Beth McCann also opposed the measure, according to her spokesperson Carolyn A. Tyler.

    “We’re still in the very early stages of marijuana legalization, and we are still learning the impact of that substance on our city,” Tyler said. “And [District Attorney McCann] is not in favor of Denver being the only city that doesn’t enforce the law.”

    Denver isn’t the only municipality changing its stance on magic mushrooms. In Iowa a lawmaker proposed a measure that would remove psychedelic mushrooms from the list of controlled substances in the state. California and Oregon also have organizations trying to get voters to consider decriminalizing mushrooms in 2020.

    View the original article at thefix.com

  • Activists Want Legalization For Psychedelics

    Activists Want Legalization For Psychedelics

    Oakland activists are holding a rally to push for the legalization of psychedelic drugs. 

    As legalized marijuana creeps into the mainstream, advocates for drug policy reform are setting their sights on a new goal—legalizing psychedelics. 

    Organizers in Oakland, California are the latest to push for legalizing psychedelic drugs including mushrooms, according to Marijuana Moment

    A Meetup post advertising efforts to “decriminalize nature” invites people to participate in a rally on March 22 in the city. 

    “With your help we can make this happen, but we need everybody’s support. Join the movement to restore our relationship to nature and advocate for our inalienable right to cognitive liberty and the freedom to explore our own consciousness,” the post reads.

    It continues, “Wouldn’t it be nice to have the freedom to work with these ancient sacred medicines that offer direct knowledge without the fear of persecution? Wouldn’t it be nice to address the set and setting elephant in the room—to reduce the immediate fear of persecution involved while engaging our right to access natural healing and insight—by decriminalizing entheogenic plants and fungi?”

    A representative of the meetup told Marijuana Moment that more details would be shared at the rally. 

    The event in Oakland isn’t entirely unusual. In Denver, an area that helped lead the movement to legalize marijuana, voters will consider a ballot measure to decriminalize psilocybin mushrooms in May. The effort is lead by Decriminalize Denver, and director Kevin Matthews said that just getting the measure on the ballot is significant. 

    “This has never been done before in the history of the U.S., so the fact that we were able to turn out the signatures and make the ballot is a strong statement that there are a lot of people who support this,” Matthews told Marijuana Moment. “We’ve created a platform where we can spread the right information about psilocybin as opposed to the misinformation and, really just downright propaganda from the government, and the war on drugs for the last almost 50 years now.”

    Matthews said that if decriminalization passes in Denver, the group may focus on more widespread change to laws regulating psychedelics. 

    He said, “We are confident that when this passes in May that it’ll open some doors to further conversation. Our big mission here is to work on reintegrating psilocybin back into society.”

    In Iowa, a new Republican lawmaker, Rep. Jeff Shipley, submitted legislation that would allow psilocybin, MDMA and ibogaine to be used in medical treatments by removing a ban on them. 

    “Exploring these issues are paramount to solving the healthcare crisis,” Shipley said in an email to Marijuana Moment. “There’s so much potential for research and clinical applications. I hope we can empower and trust patients to make their own best decisions.”

    View the original article at thefix.com

  • Microdosing Study Yields Mixed Results

    Microdosing Study Yields Mixed Results

    Researchers explored the physical and mental effects of microdosing in a new study.

    The practice of microdosing—consuming very small amounts of psychedelic substances like psilocybin, allegedly to increase mental capacities—has gained popularity among individuals who have reported greater focus, happiness and creativity from the practice.

    To determine whether these claims had any validity, researchers conducted a study that posed a daily series of questions to regular microdosing proponents about their mental and emotional responses to their chosen substances.

    Their responses—which highlighted mostly positive but also negative reactions—underscored both the researchers’ and High Times‘ assessments that the subject was worthy of further study.

    The study, conducted by researchers from Macquarie University in Sydney, Australia and published in the journal PLOS One, recruited 98 participants to conduct its research. And to circumvent any legal issues involved the study of psychedelics, all of the subjects were already involved in microdosing.

    Over the course of a six-week period, the participants were tasked with answering sets of questions on a daily basis, as well as a separate and more intensive set at the beginning and end of the six-week timeframe.

    Upon reviewing the results, the researchers found that the majority of the participants reported that their experiences were largely positive. They claimed to experience an increase in a number of areas, including creativity, focus, happiness and productivity, on days when they microdosed. Such reactions were reported less on days when doses were not taken.

    Participants also claimed that they experienced lower levels of depression and stress, though study author Vince Polito also noted that none of the 98 participants reported problems with either condition prior to the launch of the study.

    While most of the responses skewed positive, some participants also reported a slight increase in neurotic feelings at the conclusion of the six-week test. Additionally, some reported such a negative response to their first experience with the psychedelic substances that they stopped their involvement after that initial experiment. 

    Noting that the participants’ previous and/or regular experiences might cause a degree of bias in their responses, the researchers also queried a group of 263 microdosers with varying degrees of experience about pre-existing beliefs and expectations about microdosing.

    The researchers found that while all participants believed that microdosing would produce considerable and extensive benefits, what they believed would happen was markedly different than what was reported by the actual group undergoing the microdosing. 

    As High Times noted, Polito and his co-author, Richard J. Stevenson, observed that their study was based on very broad and general information, and was drawn from personal questionnaires and not scientific experiments.

    Still, Polito noted that their findings showed “promising indications of possible benefits of microdosing, [as well as] indications of some potential negative impacts, which should be taken seriously.”

    The study authors concluded that research on microdosing is in its early stages, and requires more comprehensive studies to make more specific determinations.

    View the original article at thefix.com

  • Psilocybin Trials For Depression Treatment Get Greenlight From FDA

    Psilocybin Trials For Depression Treatment Get Greenlight From FDA

    The FDA has recognized the psychedelic compound’s therapeutic potential.

    The U.S. Food and Drug Administration has granted its “Breakthrough Therapy” designation to psilocybin-assisted treatment for depression.

    By giving psilocybin research its “Breakthrough Therapy” designation, the FDA is expediting the development and review of psilocybin—the psychedelic compound in “magic mushrooms”—based on the results of preliminary clinical trials that demonstrate its potential to perform better than available treatments.

    Previous research on psilocybin has yielded promising results for treating end-of-life anxiety and depression, alcohol and tobacco use disorder and obsessive compulsive disorder.

    With the FDA’s blessing, the first large-scale clinical trial for treating refractory (treatment-resistant) depression with psilocybin will run for about one year in Europe and North America.

    Psilocybin researchers say this is a significant development in the future of the psychedelic compound’s role in medicine.

    “FDA Breakthrough status is a big deal,” Matthew Johnson, PhD, associate professor of psychiatry and behavioral sciences at Johns Hopkins University, told Inverse. “It implies that the FDA recognizes the treatment is potentially one with a large impact on a largely under-treated condition.”

    Johnson and his colleagues recommend that the federal government re-categorize psilocybin to Schedule IV, instead of its current place in Schedule I, the category reserved for drugs defined as having a high potential for abuse and no medical value.

    In Schedule IV, psilocybin would instead be in the same category as Xanax and Ambien. The scientists say that while there’s less of a risk for harm than heroin (Schedule I), “that doesn’t mean [psilocybin is] safe, and they certainly need to be regulated in some fashion.”

    But while the FDA’s Breakthrough designation suggests that psilocybin is closer to mainstream acceptance than ever, it’s unlikely that the potential treatment will be widely distributed to the general population.

    Roland Griffiths, PhD, another prominent psilocybin researcher and a colleague of Johnson’s, says, “It seems unlikely that these are compounds that will be dispensed at a pharmacy.”

    “This is a significant positive development in the potential future regulatory approval of psilocybin, a classic psychedelic drug, for medicinal purposes,” Griffiths told Inverse.

    “After a decades-long hiatus of research with psilocybin and related psychedelic drugs, investigators in the United States and Europe have demonstrated the safety and preliminary signs of efficacy of psilocybin for a variety of therapeutic applications.”

    View the original article at thefix.com

  • Could "Magic Mushrooms" Help You Stop Smoking?

    Could "Magic Mushrooms" Help You Stop Smoking?

    A new study examined whether psilocybin could help long-time smokers put down their butts for good. 

    Once dismissed as a remnant of ’60s counterculture, and eventually banned as a Schedule I drug, psilocybin—the naturally-occurring psychedelic compound found in certain species of mushrooms, thus earning them the sobriquet “magic mushrooms”—has in recent years been ushered to the forefront of medical and psychological research for its reported efficacy in treating any number of health conditions, including depression and alcoholism.

    Now, a new study suggests that psilocybin may also help to curb smoking, as evidenced by the results of six years of research involving smokers who had tried and failed to quit smoking on multiple occasions.

    The study found that through controlled psilocybin use and cognitive behavioral therapy (CBT), more than half of the participants had successfully quit smoking after a six-month period—a higher rate of abstinence than with CBT alone, according to researchers.

    The study, conducted by researchers from Johns Hopkins University, involved 15 study participants—10 men and 5 women, all at an average age of 51, and who smoked, on average, slightly less than a full pack (19 cigarettes) daily for 31 years. All had attempted to stop smoking on previous occasions, but had failed.

    The study authors administered treatment to the participants and then followed up with them over a period of six years, between 2009 and 2015.

    The treatment consisted of carefully controlled and monitored psilocybin use in conjunction with CBT. After a period of more than two years, the researchers invited the participants to take part in a follow-up interview to determine if and how the treatment affected their smoking. Twelve of the original 15 participants took part in the interview.

    What researchers found was that the 12 participants had not only succeeded in complete smoking cessation after six months, but also experienced a host of additional emotional and psychological responses to the treatment.

    Participants said that through a combination of the treatment, counseling, a “strong rapport” with the study team, and a sense of momentum after taking part in the study all contributed to their achieving abstinence.

    They also reported “gaining vivid insights into self-identity and reasons for smoking” from the psilocybin treatment, and the sense of “interconnectedness, curiosity and awe” continued after the treatment had ended. Participants also said that they felt an array of “persistent” positive feelings, including “increased aesthetic appreciation, altruism, and pro-social behavior” as a result of their participation.

    The researchers concluded that the results of their study underscored the value in continuing research into what some have labeled “psychedelic therapy,” and recommended future research trials.

    Their findings also supported previous study findings by Johns Hopkins researchers, which suggested that lifetime smokers treated with psilocybin experienced twice the rate of abstinence than those who used the FDA-approved drug Chantix.

    View the original article at thefix.com